The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Sharon Mates, insider at Intra-Cellular Therapies

Sharon Mates Insider Information

As Founder, Chairman and CEO of Intra-Cellular Therapies (ITCI), Dr. Mates leads Intra-Cellular Therapies, a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative drugs that address underserved medical needs in complex psychiatric and neurologic diseases.

Dr. Mates has more than 25 years of experience leading public and private companies with a steadfast commitment to cutting-edge science and research to discover innovative approaches to treating disease. Prior to co-founding ITCI in 2002, she was President and board member of North American Vaccine Inc. and its predecessor companies for almost a decade, during which time she oversaw the development and approval of pediatric vaccines. Throughout her career, she has held numerous advisory and board positions including a current board appointment to Biotechnology Innovation Organization Emerging Company Section (BIO ECS). Previous appointments include chairman of the New York Biotechnology Association, Board of Visitors of the Biotechnology Institute of the University of Maryland, and member of the Harvard School of Public Health Advisory Council of the Center for Society and Health.

Dr. Mates received her B.S. from The Ohio State University and her Ph.D. from the University of Washington. She completed her postdoctoral fellowships at the Massachusetts General Hospital and Harvard Medical School.

What is Sharon Mates' net worth?

The estimated net worth of Sharon Mates is at least $64.07 million as of February 19th, 2021. Dr. Mates owns 1,161,239 shares of Intra-Cellular Therapies stock worth more than $64,065,556 as of July 3rd. This net worth approximation does not reflect any other investments that Dr. Mates may own. Additionally, Dr. Mates receives a salary of $2,250,000.00 as CEO at Intra-Cellular Therapies. Learn More about Sharon Mates' net worth.

How old is Sharon Mates?

Dr. Mates is currently 69 years old. There are 7 older executives and no younger executives at Intra-Cellular Therapies. Learn More on Sharon Mates' age.

What is Sharon Mates' salary?

As the CEO of Intra-Cellular Therapies, Inc., Dr. Mates earned a total compensation package of $5,475,679.00 in 2020. Dr. Mates earned a salary of $766,800.00, a bonus of $690,120.00, stock awards of $2,799,998.00, options awards of $1,199,994.00, and other compensation of $18,767.00. Learn More on Sharon Mates' salary.

How do I contact Sharon Mates?

The corporate mailing address for Dr. Mates and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected] Learn More on Sharon Mates' contact information.

Has Sharon Mates been buying or selling shares of Intra-Cellular Therapies?

Sharon Mates has not been actively trading shares of Intra-Cellular Therapies during the last ninety days. 0 shares of BMO Capital Markets stock in a transaction that occurred on Sunday, July 3rd. Learn More on Sharon Mates' trading history.

Who are Intra-Cellular Therapies' active insiders?

Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), and Rory Riggs (Director). Learn More on Intra-Cellular Therapies' active insiders.

Are insiders buying or selling shares of Intra-Cellular Therapies?

During the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 799,628 shares worth more than $40,211,799.12. The most recent insider tranaction occured on May, 12th when Director Joel S Marcus sold 10,000 shares worth more than $550,000.00. Insiders at Intra-Cellular Therapies own 13.2 % of the company. Learn More about insider trades at Intra-Cellular Therapies.

Information on this page was last updated on 5/12/2022.

Sharon Mates Insider Trading History at Intra-Cellular Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/24/2022Sell22,589$51.98$1,174,176.22View SEC Filing Icon  
2/22/2022Sell27,847$55.39$1,542,445.33View SEC Filing Icon  
1/10/2022Sell41,896$40.78$1,708,518.88View SEC Filing Icon  
10/18/2021Sell8,192$40.00$327,680.00View SEC Filing Icon  
10/15/2021Sell40,392$40.00$1,615,680.00View SEC Filing Icon  
2/19/2021Sell27,847$39.23$1,092,437.811,161,239View SEC Filing Icon  
1/11/2021Sell41,896$32.01$1,341,090.961,175,288View SEC Filing Icon  
1/4/2021Sell48,341$31.30$1,513,073.30
11/4/2020Sell50,000$25.00$1,250,000.001,163,392View SEC Filing Icon  
1/9/2020Sell41,895$26.16$1,095,973.201,204,707View SEC Filing Icon  
1/6/2020Sell45,598$30.28$1,380,707.441,182,366View SEC Filing Icon  
1/2/2020Sell17,478$32.45$567,161.101,156,185View SEC Filing Icon  
1/7/2019Sell6,604$12.43$82,087.721,190,909View SEC Filing Icon  
1/4/2019Sell45,598$11.45$522,097.101,190,909View SEC Filing Icon  
1/2/2019Sell17,478$11.09$193,831.021,156,185View SEC Filing Icon  
1/8/2018Sell6,604$17.48$115,437.921,088,707View SEC Filing Icon  
1/5/2018Sell11,257$17.08$192,269.561,099,964View SEC Filing Icon  
10/30/2017Sell18,750$15.75$295,312.501,107,457View SEC Filing Icon  
1/5/2017Sell4,081$16.55$67,540.551,088,707View SEC Filing Icon  
12/11/2015Sell51,500$53.87$2,774,305.001,086,185View SEC Filing Icon  
See Full Table

Sharon Mates Buying and Selling Activity at Intra-Cellular Therapies

This chart shows Sharon Mates's buying and selling at Intra-Cellular Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $55.17
Low: $53.13
High: $57.12

50 Day Range

MA: $55.10
Low: $43.00
High: $59.41

2 Week Range

Now: $55.17
Low: $28.40
High: $66.00

Volume

896,500 shs

Average Volume

736,741 shs

Market Capitalization

$5.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!